Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year?

Akero Therapeutics (AKRO) has significantly outperformed its Medical sector and industry peers this year, posting a 70.7% year-to-date return compared to the sector's average -0.4% and its specific industry's 4.9% gain. The stock holds a Zacks Rank #2 (Buy), supported by a 4.9% upward revision in its full-year earnings consensus estimate over the past quarter, indicating strengthening analyst sentiment and an improving earnings outlook. Humana (HUM) also exhibits positive momentum with a 2.6% YTD return and a Zacks Rank #2 (Buy).

Analysis

Akero Therapeutics (AKRO) has demonstrated significant market outperformance, registering a 70.7% year-to-date return that starkly contrasts with the broader Medical sector's average return of -0.4% and its direct Medical - Biomedical and Genetics industry's gain of 4.9%. This upward momentum is underpinned by improving fundamentals, as evidenced by a 4.9% increase in the consensus full-year earnings estimate over the last quarter, which has contributed to its Zacks Rank of #2 (Buy). The data indicates strengthening analyst sentiment and an improving earnings outlook for the company. In a similar vein, Humana (HUM) is also outperforming, with a 2.6% year-to-date gain and an upgraded consensus EPS estimate of 3.8% over the past three months, also securing a Zacks Rank #2 (Buy). Humana's performance is particularly noteworthy as it has occurred while its Medical - HMOs industry has declined by 26% year-to-date, positioning it as a resilient player in a challenged sub-sector.

Key Decisions for Investors

• Investors seeking growth within the biotech space should evaluate Akero Therapeutics, as its substantial 70.7% year-to-date return and positive earnings estimate revisions signal strong momentum compared to its peers.
• For those looking for relative strength in a challenged sub-sector, Humana warrants consideration due to its positive performance and improving earnings outlook in contrast to the significant -26% decline in the Medical - HMOs industry.
• Given that the bullish theses for both AKRO and HUM are heavily influenced by recent upward earnings estimate revisions and their associated Zacks Ranks, it is critical to monitor future analyst consensus reports for any shifts in sentiment or decelerating momentum which could alter the investment case.